No Data
No Data
Express News | Personalis Provides Dial-in and Updated Date for Asco Highlights Conference Call
ASCO Data Highlights NeXT Personal Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference Personalis, Inc. (NASDAQ:PSNL) announced today that data
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Tempus Announces the Clinical Launch of Its MRD Testing Portfolio
xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoringCHICAGO--(BUSINESS WIRE)--Tempus, a leader in artifi
Express News | Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Express News | Personalis Announces Start of Cancer Mrd Testing Commercialization Collaboration With Tempus
No Data